Basic HTML Version
BIOFLOW-I trial design
Clinical endpoint
assessment
Angiographic & IVUS
endpoint assessment
30 d
4 mo
9 mo 12 mo
2 yr
3 yr
•
Design:
Prospective, multi-centre, first in man trial
•
Patient Number:
30
•
Patents with angiographic follow-up:
30
•
Patients with IVUS follow-up:
15
•
Follow-up rate:
100%
•
Enrollment time:
Between 02
–
23 July 2009